BretonMD, KovatchevBP: One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther, 2021; 23:601-608.
2.
BrownSA, KovatchevBP, RaghinaruD, et al.; for the iDCL Trial Research Group: 6-month randomized multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381:1707–1717.
3.
BretonMD, KanapkaLG, BeckRW, et al.; for the iDCL Trial Research Group: A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383:836–845.
4.
PetrovskiG, Al KhalafF, CampbellJ, et al.: One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol, 2021; 58:207–213.
5.
LalRA, BasinaM, MaahsDM, et al.: One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care, 2019; 42:2190–2196.
6.
BergetC, MesserLH, VigersT, et al.: Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system. Pediatr Diabetes, 2019; 21:310–318.
7.
AkturkHK, GiordanoD, ChampakanathA, et al.: Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab, 2020; 22:583–589.
